Abstract
The immunohistochemical classification of Human Epidermal Growth Factor Receptor 2 (HER2) expression is optimized to detect HER2-amplified breast cancer (BC). However, novel HER2 targeting agents are also effective for BCs with low levels of HER2 expression. This raises the question whether the current guidelines for HER2-testing are sufficiently reproducible to identify HER2 low BC. The aim of this multicenter international study was to assess the interobserver agreement of HER2 low scoring according to the current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
